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Other names: DKFZp781P1017; LOT1; MGC126275; 




The genome is about 64 kbp with six exons and five 
introns. The major mRNA transcript is about 4.7 kb in 
size. 
Transcription 
At least three splicing variants (see figure). 
Protein 
Description 
The PLAGL1 protein is a seven C2H2-type zinc finger 
protein. The seven zinc finger domain is located at the 
amino terminal region, from the amino acid residue 1 to 
210. Additional features of note are proline and 
glutamine rich regions at the carboxyl terminal portion 
(residues 220 to 444). There are two nuclear 
localization signals at the amino terminal region. 
Expression 
Ovary, breast, brain, liver, spleen, thymus, prostate, 




The PLAGL1 protein is a candidate tumor suppressor 




Schematic view of the PLAGL1 gene. A. The six exons, shown in red, are 326; 72; 1443; 75; 475; 2380 bp, respectively. The introns are 
approximately 39; 2.6; 4.2; 12.5; 5.5 kbp in size, respectively. B. The figure shows three splice variants of PLAGL1; the exons are shown 
as a box. 
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Homology 
Homologous to the mouse and Rat plagl1 and to the 
human PLAG1 and PLAGL2 proteins. 
Mutations 




Note: Alteration of the gene expression was found to 
be a potential genetic event silencing the PLAGL1 gene 
in cancers such as breast primary tumors, ovarian 
primary tumors and tumor-derived cell lines, basal cell 
carcinoma, head and neck squamous cell carcinoma 
(HNSCC), and extraskeletal myxoid chondrosarcoma 
(EMC). Several mechanisms have been shown to 
regulate the PLAGL1 gene expression, including 
growth factor receptor activation, epigenetic factors, 
maternal imprinting, and loss of heterozygosity (LOH). 
Allelic deletion of 6q24-q25, the PLAGL1 locus, in the 
tumor tissues has been shown in the cancers of ovarian, 
breast, HNSCC, and pheochromocytomas (PCCs). 
Disease 
Cancer 
Transient neonatal diabetes (TNDM) 
Note: Initial reports suggested that transient neonatal 
diabetes mellitus (TNDM), a rare condition 
characterized in the patients by intrauterine growth 
retardation, dehydration, failure to thrive, and 
hyperglycemia due to a lack of normal insulin 
secretion, is associated with paternal uniparental 
disomy (UPD) of chromosome 6 (UPD 6). Later 
studies showed the involvement of an imprinted gene in 
this disease within the chromosomal region 6q24.1-
q24.3 between markers D6S1699 and D6S1010. 
Analysis of the CpG islands in the TNDM critical 
region, using DNA from TNDM patients with paternal 
UPD 6 and normal controls, suggested 
PLAGL1/LOT1/ZAC1 as a candidate imprinted gene 
for this disease. 
Disease 
Diabetes mellitus 
To be noted 
Note: PLAGL1 has been implicated in embryonic 
development. The gene is variably expressed in 
different tissues and stages during development. 
Inactivation of this maternally repressed gene resulted 
in intrauterine growth restriction, altered bone 
formation, and neonatal lethality. 
 
References 
Abdollahi A, Roberts D, Godwin AK, Schultz DC, Sonoda G, 
Testa JR, Hamilton TC. Identification of a zinc-finger gene at 
6q25: a chromosomal region implicated in development of 
many solid tumors. Oncogene 1997;14(16):1973-1979. 
Abdollahi A, Godwin AK, Miller PD, Getts LA, Schultz DC, 
Taguchi T, Testa JR, Hamilton TC. Identification of a gene 
containing zinc-finger motifs based on lost expression in 
malignantly transformed rat ovarian surface epithelial cells. 
Cancer Res 1997;57(10):2029-2034. 
Spengler D, Villalba M, Hoffmann A, Pantaloni C, Houssami S, 
Bockaert J, Journot L. Regulation of apoptosis and cell cycle 
arrest by Zac1, a novel zinc finger protein expressed in the 
pituitary gland and the brain. EMBO J 1997;16(10):2814-2825. 
Gillardon F, Hata R, Hossmann KA. Delayed up-regulation of 
Zac1 and PACAP type I receptor after transient focal cerebral 
ischemia in mice. Brain Res Mol Brain Res 1998;61(1-2):207-
210. 
Kas K, Voz ML, Hensen K, Meyen E, Van de Ven WJ. 
Transcriptional activation capacity of the novel PLAG family of 
zinc finger proteins. J Biol Chem 1998;273(36):23026-23032. 
Varrault A, Ciani E, Apiou F, Bilanges B, Hoffmann A, 
Pantaloni C, Bockaert J, Spengler D, Journot L. hZAC encodes 
a zinc finger protein with antiproliferative properties and maps 
to a chromosomal region frequently lost in cancer. Proc Natl 
Acad Sci USA 1998;95(15):8835-8840. 
Abdollahi A, Bao R, Hamilton TC. LOT1 is a growth suppressor 
gene down-regulated by the epidermal growth factor receptor 
ligands and encodes a nuclear zinc-finger protein. Oncogene 
1999;18(47):6477-6487. 
Bilanges B, Varrault A, Basyuk E, Rodriguez C, Mazumdar A, 
Pantaloni C, Bockaert J, Theillet C, Spengler D, Journot L. 
Loss of expression of the candidate tumor suppressor gene 
ZAC in breast cancer cell lines and primary tumors. Oncogene 
1999;18(27):3979-3988. 
Pagotto U, Arzberger T, Ciani E, Lezoualc'h F, Pilon C, Journot 
L, Spengler D, Stalla GK. Inhibition of Zac1, a new gene 
differentially expressed in the anterior pituitary, increases cell 
proliferation. Endocrinology 1999;140(2):987-996. 
Arima T, Drewell RA, Oshimura M, Wake N, Surani MA. A 
novel imprinted gene, HYMAI, is located within an imprinted 
domain on human chromosome 6 containing ZAC. Genomics 
2000;67(3):248-255. 
Huang SM, Stallcup MR. Mouse Zac1, a transcriptional 
coactivator and repressor for nuclear receptors. Mol Cell Biol 
2000;20(5):1855-1867. 
Kamiya M, Judson H, Okazaki Y, Kusakabe M, Muramatsu M, 
Takada S, Takagi N, Arima T, Wake N, Kamimura K, Satomura 
K, Hermann R, Bonthron DT, Hayashizaki Y. The cell cycle 
control gene ZAC/PLAGL1 is imprinted--a strong candidate 
gene for transient neonatal diabetes. Hum Mol Genet 
2000;9(3):453-460. 
Pagotto U, Arzberger T, Theodoropoulou M, Grübler Y, 
Pantaloni C, Saeger W, Losa M, Journot L, Stalla GK, 
Spengler D. The expression of the antiproliferative gene ZAC 
is lost or highly reduced in nonfunctioning pituitary adenomas. 
Cancer Res 2000;60(24):6794-6799. 
Piras G, El Kharroubi A, Kozlov S, Escalante-Alcalde D, 
Hernandez L, Copeland NG, Gilbert DJ, Jenkins NA, Stewart 
CL. Zac1 (Lot1), a potential tumor suppressor gene, and the 
gene for epsilon-sarcoglycan are maternally imprinted genes: 






Atlas Genet Cytogenet Oncol Haematol. 2008;12(2)  129 
identification by a subtractive screen of novel uniparental 
fibroblast lines. Mol Cell Biol 2000;20(9):3308-3315. 
Bilanges B, Varrault A, Mazumdar A, Pantaloni C, Hoffmann A, 
Bockaert J, Spengler D, Journot L. Alternative splicing of the 
imprinted candidate tumor suppressor gene ZAC regulates its 
antiproliferative and DNA binding activities. Oncogene 
2001;20(10):1246-1253. 
Huang SM, Schönthal AH, Stallcup MR. Enhancement of p53-
dependent gene activation by the transcriptional coactivator 
Zac1. Oncogene 2001;20(17):2134-2143. 
Valente T, Auladell C. Expression pattern of Zac1 mouse gene, 
a new zinc-finger protein that regulates apoptosis and cellular 
cycle arrest, in both adult brain and along development. Mech 
Dev 2001;108(1-2):207-211. 
Varrault A, Bilanges B, Mackay DJ, Basyuk E, Ahr B, 
Fernandez C, Robinson DO, Bockaert J, Journot L. 
Characterization of the methylation-sensitive promoter of the 
imprinted ZAC gene supports its role in transient neonatal 
diabetes mellitus. J Biol Chem 2001;276(22):18653-18656. 
Hensen K, Van Valckenborgh IC, Kas K, Van de Ven WJ, Voz 
ML. The tumorigenic diversity of the three PLAG family 
members is associated with different DNA binding capacities. 
Cancer Res 2002;62(5):1510-1517. 
Mackay DJ, Coupe AM, Shield JP, Storr JN, Temple IK, 
Robinson DO. Relaxation of imprinted expression of ZAC and 
HYMAI in a patient with transient neonatal diabetes mellitus. 
Hum Genet 2002;110(2):139-144. 
Smith RJ, Arnaud P, Konfortova G, Dean WL, Beechey CV, 
Kelsey G. The mouse Zac1 locus: basis for imprinting and 
comparison with human ZAC. Gene 2002;292(1-2):101-112. 
Abdollahi A, Pisarcik D, Roberts D, Weinstein J, Cairns P, 
Hamilton TC. LOT1 (PLAGL1/ZAC1), the candidate tumor 
suppressor gene at chromosome 6q24-25, is epigenetically 
regulated in cancer. J Biol Chem 2003;278(8):6041-6049. 
Ciani E, Frenquelli M, Contestabile A. Developmental 
expression of the cell cycle and apoptosis controlling gene, 
Lot1, in the rat cerebellum and in cultures of cerebellar granule 
cells. Brain Res Dev Brain Res 2003;142(2):193-202. 
Hoffmann A, Ciani E, Boeckardt J, Holsboer F, Journot L, 
Spengler D. Transcriptional activities of the zinc finger protein 
Zac are differentially controlled by DNA binding. Mol Cell Biol 
2003;23(3):988-1003. 
Cvetkovic D, Pisarcik D, Lee C, Hamilton TC, Abdollahi A. 
Altered expression and loss of heterozygosity of the LOT1 
gene in ovarian cancer. Gynecol Oncol 2004;95(3):449-455. 
Koy S, Hauses M, Appelt H, Friedrich K, Schackert HK, Eckelt 
U. Loss of expression of ZAC/LOT1 in squamous cell 
carcinomas of head and neck. Head Neck 2004;26(4):338-344. 
Valente T, Domínguez MI, Bellmann A, Journot L, Ferrer I, 
Auladell C. Zac1 is up-regulated in neural cells of the limbic 
system of mouse brain following seizures that provoke strong 
cell activation. Neuroscience 2004;128(2):323-336. 
Arima T, Kamikihara T, Hayashida T, Kato K, Inoue T, 
Shirayoshi Y, Oshimura M, Soejima H, Mukai T, Wake N. ZAC, 
LIT1 (KCNQ1OT1) and p57KIP2 (CDKN1C) are in an 
imprinted gene network that may play a role in Beckwith-
Wiedemann syndrome. Nucleic Acids Res 2005;33(8):2650-
2660. 
Basyuk E, Coulon V, Le Digarcher A, Coisy-Quivy M, Moles 
JP, Gandarillas A, Journot L. The candidate tumor suppressor 
gene ZAC is involved in keratinocyte differentiation and its 
expression is lost in basal cell carcinomas. Mol Cancer Res 
2005;3(9):483-492. 
Contestabile A, Fila T, Bartesaghi R, Ciani E. Cyclic AMP-
mediated regulation of transcription factor Lot1 expression in 
cerebellar granule cells. J Biol Chem 2005;280(39):33541-
33551. 
Kamikihara T, Arima T, Kato K, Matsuda T, Kato H, Douchi T, 
Nagata Y, Nakao M, Wake N. Epigenetic silencing of the 
imprinted gene ZAC by DNA methylation is an early event in 
the progression of human ovarian cancer. Int J Cancer 
2005;115(5):690-700. 
Poulin H, Labelle Y. The PLAGL1 gene is down-regulated in 
human extraskeletal myxoid chondrosarcoma tumors. Cancer 
Lett 2005;227(2):185-191. 
Valente T, Junyent F, Auladell C. Zac1 is expressed in 
progenitor/stem cells of the neuroectoderm and mesoderm 
during embryogenesis: differential phenotype of the Zac1-
expressing cells during development. Dev Dyn 
2005;233(2):667-679. 
Arima T, Yamasaki K, John RM, Kato K, Sakumi K, 
Nakabeppu Y, Wake N, Kono T. The human HYMAI/PLAGL1 
differentially methylated region acts as an imprint control 
region in mice. Genomics 2006;88(5):650-658. 
Arima T, Wake N. Establishment of the primary imprint of the 
HYMAI/PLAGL1 imprint control region during oogenesis. 
Cytogenet Genome Res 2006;113(1-4):247-252. 
Barz T, Hoffmann A, Panhuysen M, Spengler D. Peroxisome 
proliferator-activated receptor gamma is a Zac target gene 
mediating Zac antiproliferation. Cancer Res 
2006;66(24):11975-11982. 
Hoffmann A, Barz T, Spengler D. Multitasking C2H2 zinc 
fingers link Zac DNA binding to coordinated regulation of p300-
histone acetyltransferase activity. Mol Cell Biol 
2006;26(14):5544-5557. 
Varrault A, Gueydan C, Delalbre A, Bellmann A, Houssami S, 
Aknin C, Severac D, Chotard L, Kahli M, Le Digarcher A, 
Pavlidis P, Journot L. Zac1 regulates an imprinted gene 
network critically involved in the control of embryonic growth. 
Dev Cell 2006;11(5):711-722. 
Abdollahi A. LOT1 (ZAC1/PLAGL1) and its family members: 
mechanisms and functions. J Cell Physiol 2007;210(1):16-25. 
(Review). 
Ma L, Cantrup R, Varrault A, Colak D, Klenin N, Gotz M, 
McFarlane S, Journot L, Schuurmans C. Zac1 functions 
through TGFbetaII to negatively regulate cell number in the 
developing retina. Neural Develop 2007;2:11. 
Valleley EM, Cordery SF, Bonthron DT. Tissue-specific 
imprinting of the ZAC/PLAGL1 tumour suppressor gene results 
from variable utilization of monoallelic and biallelic promoters. 
Hum Mol Genet 2007;16(8):972-981. 
Wu MH, Huang CJ, Liu ST, Liu PY, Ho CL, Huang SM. 
Physical and functional interactions of human papillomavirus 
E2 protein with nuclear receptor coactivators. Biochem 
Biophys Res Commun 2007;356(3):523-528. 
This article should be referenced as such: 
Abdollahi A. PLAGL1 (pleomorphic adenoma gene-like 1). 
Atlas Genet Cytogenet Oncol Haematol.2008;12(2):127-129.  
 
 
 
